TrialCancer research and treatment2024

Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.

Ruyan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.